Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

How quickly can we meaningfully change symptoms in CSU, and does it last? Dr. Brownstone breaks down what the REMIX data suggest about speed, durability, and real-world relevance.

In this explainer, Nicholas Brownstone, MD, walks through pooled phase 3 data from REMIX-1 and REMIX-2, focusing on what clinicians tend to notice first: how fast patients feel better. Improvements in UAS7, itch, and hive severity begin as early as week 1, with separation from placebo that continues through week 24 and holds out to week 52.  

Just as important, patients who started on placebo and later transitioned to remibrutinib reached similar levels of symptom control by the end of the study—pointing to both consistency and durability over time. The full poster adds context on safety and tolerability, but the takeaway here is straightforward: rapid onset paired with sustained control in a population that often cycles through incomplete responses.